PURAPHARM (01498) disclosed its financial results for the fiscal year ended December 31, 2025. The group reported revenue of HK$336 million, representing a 12% year-on-year decrease. The net loss amounted to HK$35.223 million, showing a slight narrowing of 0.6% compared to the previous year. The basic loss per share was HK 8.41 cents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.